FDA still finding same cGMP deficiencies at dietary supplement facilities

FDA investigators who inspect dietary supplement manufacturing facilities for compliance with cGMPs (current good manufacturing practices) are still often finding the same deficiencies more than a decade after the regulations were adopted. In fiscal year 2018 (FY18), 75 inspections—or about 24 percent of firms that received a Form 483 inspection report for “observations,” or alleged…

Sugar reduction in sports nutrition applications

The sports nutrition market continues to see steady growth. Athletes and mainstream users, including exercisers and those leading active lifestyles, are looking for products that support their recreational and lifestyle-driven performance. Both men and women seek sports nutrition products to help improve their nutritional intake, general health, well-being, performance, and muscle growth and recovery from…

FDA issues guidance on disclosing amount of live microbial ingredients in supplements

FDA on Thursday recognized the benefits of disclosing on labels the number of live microbials in dietary supplements—an issue of interest to marketers of probiotics. FDA stopped short of amending its labeling regulations, denying a request filed by the International Probiotics Association (IPA). However, the agency revealed plans to “exercise enforcement discretion” for companies that…

CRN Voluntary Guidelines Reinforce Industry Commitment to Consumer Safety

The Council for Responsible Nutrition (CRN) has unveiled two developments in its collection of proactive, science-based voluntary guidelines and best practices: new recommended guidelines for products containing SARMs and updates to its recommended guidelines for caffeine-containing dietary supplements.These updates coincide with recent FDA action to protect consumers from the potentially harmful effects of selective androgen…

FDA Approves CBD Medicine, Signals Enforcement Priorities Against Unapproved Products

FDA on Monday announced approval of a cannabidiol (CBD)-based drug derived from marijuana, and its top official signaled where the agency will focus its enforcement priorities against companies marketing unapproved CBD products. Epidiolex, the medicine developed by GW Pharmaceuticals plc, was approved by FDA to treat seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in patients…